Onkure Therapeutics Inc
OKUR2.160USD
-0.040-1.82%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
29.03MCap. mercado
PérdidaP/E TTM
Más Datos de Onkure Therapeutics Inc Compañía
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KαH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3Kα and has multiple programs designed to enable targeting of this key oncogene.
Información de la empresa
Símbolo de cotizaciónOKUR
Nombre de la empresaOnkure Therapeutics Inc
Fecha de salida a bolsaApr 09, 2021
Director ejecutivoDr. Nicholas A. Saccomano, Ph.D.
Número de empleados46
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 09
Dirección6707 Winchester Circle, Suite 400
CiudadBOULDER
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal80301
Teléfono17203072892
Sitio Webhttps://onkuretherapeutics.com/
Símbolo de cotizaciónOKUR
Fecha de salida a bolsaApr 09, 2021
Director ejecutivoDr. Nicholas A. Saccomano, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
9.78K
+181.93%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dylan Hartley, Ph.D.
Dr. Dylan Hartley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ed T. Mathers ,
Ed T. Mathers ,
Independent Director
Independent Director
--
--
Ms. Valerie M. Jansen, M.D., Ph.D.
Ms. Valerie M. Jansen, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
9.78K
+181.93%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: lun., 28 de jul
Actualizado: lun., 28 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Acorn Capital Advisors, LLC
22.14%
Citadel Advisors LLC
8.33%
Perceptive Advisors LLC
7.83%
Samsara BioCapital, LLC
6.43%
Shay Capital LLC
6.32%
Other
48.95%
Accionistas
Accionistas
Proporción
Acorn Capital Advisors, LLC
22.14%
Citadel Advisors LLC
8.33%
Perceptive Advisors LLC
7.83%
Samsara BioCapital, LLC
6.43%
Shay Capital LLC
6.32%
Other
48.95%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
30.57%
Investment Advisor
30.02%
Venture Capital
15.38%
Private Equity
11.67%
Investment Advisor/Hedge Fund
10.55%
Individual Investor
1.66%
Research Firm
0.10%
Other
0.06%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
185
12.82M
99.94%
-1.09M
2025Q1
187
12.71M
99.28%
-1.05M
2024Q4
190
12.64M
105.50%
+4.22M
2024Q3
172
2.79M
546.32%
-1.40M
2024Q2
171
3.11M
93.03%
-1.12M
2024Q1
161
3.05M
91.28%
-864.58K
2023Q4
152
2.81M
85.98%
-309.72K
2023Q3
128
3.01M
91.00%
-83.83K
2023Q2
119
2.90M
88.58%
+621.98K
2023Q1
109
1.98M
78.98%
-170.10K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Acorn Capital Advisors, LLC
2.84M
22.14%
+1.40M
+97.24%
May 15, 2025
Citadel Advisors LLC
1.07M
8.33%
-6.21K
-0.58%
Mar 31, 2025
Perceptive Advisors LLC
1.00M
7.83%
--
--
Mar 31, 2025
Samsara BioCapital, LLC
824.15K
6.43%
--
--
Mar 31, 2025
Shay Capital LLC
810.21K
6.32%
+659.18K
+436.43%
May 15, 2025
The Vanguard Group, Inc.
706.73K
5.51%
--
--
Mar 31, 2025
Vestal Point Capital, LP
635.00K
4.95%
--
--
Mar 31, 2025
Deep Track Capital LP
523.99K
4.09%
--
--
Mar 31, 2025
StepStone Group LP
491.94K
3.84%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
478.55K
3.73%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Global X Russell 2000 ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ALPS Medical Breakthroughs ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Ver más
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
Invesco Nasdaq Biotechnology ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
ALPS Medical Breakthroughs ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Fecha
Tipo
Relación
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
